{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-205044","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.322268+00:00","generated_at":"2026-05-14T23:35:10.644359+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"FibroBiologics grants stock options to four top executives at $1.38 per share","bullets":["CEO Pete O'Heeron granted options for 92,410 shares; CFO, CSO, and General Counsel each granted 61,607 shares.","Vesting: 1/4th on first anniversary, then monthly over 36 months, subject to continuous service.","Total of 277,231 stock options granted under the 2022 Stock Plan on May 4, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-205044","json":"https://secwatch.observer/filing/0001193125-26-205044.json","markdown":"https://secwatch.observer/filing/0001193125-26-205044.md","text":"https://secwatch.observer/filing/0001193125-26-205044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526205044/0001193125-26-205044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526205044/fblg-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:35:10.644359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}